The Biomed company Epitomee’s share value spiked this month (188%) after its new weight loss pill was approved by the FDA. The pill, which inherited its company’s name will join the fierce competition between weight loss pills in the market.
In complete contrast to Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro, Epitomee’s capsule does not contain any active substance. It is a sophisticated pill that, after being swallowed and arriving at its intended destination, expands and changes its shape into a rigid triangle, in response to the acidic environment. In doing so, it mimics the presence of solid food, which causes the stomach to feel full and activate the brain’s sections of feeling satisfaction after eating. The pill lasts a few hours in the stomach and later moves to the intestines to break down within a few minutes.
Keep reading at ynetnews.com.
Epitomee Medical Co-founder and Chairman of the Board Shimon Eckhouse is a Technion alumnus.
